COPENHAGEN, Denmark, March 23, 2017 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will host a conference call and webcast on Monday, April 3 during ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida, to discuss new data regarding its three rare disease pipeline candidates (TransCon Growth Hormone, TransCon PTH and TransCon CNP). Ascendis is presenting eight posters, including two late-breakers, during the ENDO 2017 conference. Details for the Ascendis conference call and webcast include: Date...
|
